Samuel J. O'BrienAssociateSheppard, Mullin, Richter & Hampton LLPWebsitewww.sheppardmullin.comOrganization ProfileFull ProfileConnectEmail424.288.5316 Professional Biography Samuel O'Brien is an associate in the Corporate Practice Group in the firm's Century City office and is a member of the firm’s Healthcare team. More Legal and Business Bylines From Samuel J. O'Brien House Democrats Propose New Legislation to Bolster the ACA - (Posted On Saturday, June 27, 2020) HHS Further Relaxes HIPAA Regulations Governing Use and Disclosure of Protected Health Information During the COVID-19 Public Health Emergency - (Posted On Tuesday, April 14, 2020) Bipartisan Push To Repeal ACA’s Cadillac Tax - (Posted On Wednesday, September 25, 2019) Current Legal Analysis Biomanufacturing Interagency Working Group Identifies Actions to Increase U.S. Biomanufacturing Capacity by: Lynn L. Bergeson , Carla N. Hutton Louisiana Court Clarifies Employee Non-Solicitation Provision Requirements by: Joseph F. Lavigne ECHA and Five National Authorities Issue Progress Update on REACH Restriction by: Lynn L. Bergeson , Carla N. Hutton OFCCP Issues First FY 2025 CSAL, Targeting 2,000 Establishments of Supply and Service Federal Contractors and Subcontractors for Audits by: T. Scott Kelly , Lauren B. Hicks California Voters Reject Statewide $18 Minimum Wage for All Employees by: Charles L. Thompson, IV , Zachary V. Zagger EPA Extends Deadline for Public Comment on Manufacture of Certain PFAS during Fluorination of HDPE and Other Plastic Containers by: Lynn L. Bergeson , Carla N. Hutton Upcoming Events Dec 10 2024 Legal AI Week 2024 Nov 21 2024 Third-Party Litigation Funding through a Transatlantic Lens Nov 21 2024 CC&Rs and Easements for Mixed-Use Projects: Best Practices for Developers Nov 21 2024 AI Patent Eligibility: Processing the USPTO's New Guidance Nov 21 2024 Update of 2024 California Employment Law Cases Nov 25 2024 2024 Election: Impact on the Health Care Legal and Policy Landscape Webinar Dec 4 2024 TSCA 30/30 - December 4, 2024 Dec 4 2024 GLP-1 Drugs: What's Next after FDA's Resolution of Drug Shortages Print
